Files in this item
Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy
Item metadata
dc.contributor.author | Zeltins, Andris | |
dc.contributor.author | West, Jonathan | |
dc.contributor.author | Zabel, Franziska | |
dc.contributor.author | El Turabi, Aadil | |
dc.contributor.author | Balke, Ina | |
dc.contributor.author | Haas, Stefanie | |
dc.contributor.author | Maudrich, Melanie | |
dc.contributor.author | Storni, Federico | |
dc.contributor.author | Engeroff, Paul | |
dc.contributor.author | Jennings, Gary T | |
dc.contributor.author | Kotecha, Abhay | |
dc.contributor.author | Stuart, David I | |
dc.contributor.author | Foerster, John | |
dc.contributor.author | Bachmann, Martin F | |
dc.date.accessioned | 2019-08-13T14:30:07Z | |
dc.date.available | 2019-08-13T14:30:07Z | |
dc.date.issued | 2017-10-23 | |
dc.identifier.citation | Zeltins , A , West , J , Zabel , F , El Turabi , A , Balke , I , Haas , S , Maudrich , M , Storni , F , Engeroff , P , Jennings , G T , Kotecha , A , Stuart , D I , Foerster , J & Bachmann , M F 2017 , ' Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy ' , npj Vaccines , vol. 2 , 30 . https://doi.org/10.1038/s41541-017-0030-8 | en |
dc.identifier.issn | 2059-0105 | |
dc.identifier.other | PURE: 260534123 | |
dc.identifier.other | PURE UUID: e9d18eac-eff7-4152-a383-2457b989eec8 | |
dc.identifier.other | PubMed: 29263885 | |
dc.identifier.other | PubMedCentral: PMC5653761 | |
dc.identifier.other | Scopus: 85042174177 | |
dc.identifier.uri | https://hdl.handle.net/10023/18307 | |
dc.description.abstract | Monoclonal antibodies are widely used to treat non-infectious conditions but are costly. Vaccines could offer a cost-effective alternative but have been limited by sub-optimal T-cell stimulation and/or weak vaccine responses in recipients, for example, in elderly patients. We have previously shown that the repetitive structure of virus-like-particles (VLPs) can effectively bypass self-tolerance in therapeutic vaccines. Their efficacy could be increased even further by the incorporation of an epitope stimulating T cell help. However, the self-assembly and stability of VLPs from envelope monomer proteins is sensitive to geometry, rendering the incorporation of foreign epitopes difficult. We here show that it is possible to engineer VLPs derived from a non human-pathogenic plant virus to incorporate a powerful T-cell-stimulatory epitope derived from Tetanus toxoid. These VLPs (termed CMVTT) retain self-assembly as well as long-term stability. Since Th cell memory to Tetanus is near universal in humans, CMVTT-based vaccines can deliver robust antibody-responses even under limiting conditions. By way of proof of concept, we tested a range of such vaccines against chronic inflammatory conditions (model: psoriasis, antigen: interleukin-17), neurodegenerative (Alzheimer's, β-amyloid), and allergic disease (cat allergy, Fel-d1), respectively. Vaccine responses were uniformly strong, selective, efficient in vivo, observed even in old mice, and employing low vaccine doses. In addition, randomly ascertained human blood cells were reactive to CMVTT-VLPs, confirming recognition of the incorporated Tetanus epitope. The CMVTT-VLP platform is adaptable to almost any antigen and its features and performance are ideally suited for the design of vaccines delivering enhanced responsiveness in aging populations. | |
dc.format.extent | 13 | |
dc.language.iso | eng | |
dc.relation.ispartof | npj Vaccines | en |
dc.rights | © The Author(s) 2017. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visithttp://creativecommons.org/licenses/by/4.0/. | en |
dc.subject | QR180 Immunology | en |
dc.subject | RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry | en |
dc.subject | RL Dermatology | en |
dc.subject | NDAS | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject.lcc | QR180 | en |
dc.subject.lcc | RC0321 | en |
dc.subject.lcc | RL | en |
dc.title | Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy | en |
dc.type | Journal article | en |
dc.description.version | Publisher PDF | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.identifier.doi | https://doi.org/10.1038/s41541-017-0030-8 | |
dc.description.status | Peer reviewed | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.